Sause William E, Buckley Peter T, Strohl William R, Lynch A Simon, Torres Victor J
Department of Microbiology, New York University School of Medicine, New York, NY 10016, USA.
Janssen Research & Development LLC, 1400 McKean Road, Spring House, PA 19477, USA.
Trends Pharmacol Sci. 2016 Mar;37(3):231-241. doi: 10.1016/j.tips.2015.11.008. Epub 2015 Dec 22.
The growing incidence of serious infections mediated by methicillin-resistant Staphylococcus aureus (MRSA) strains poses a significant risk to public health. This risk is exacerbated by a prolonged void in the discovery and development of truly novel antibiotics and the absence of a vaccine. These gaps have created renewed interest in the use of biologics in the prevention and treatment of serious staphylococcal infections. In this review, we focus on efforts towards the discovery and development of antibody-based biologic agents and their potential as clinical agents in the management of serious S. aureus infections. Recent promising data for monoclonal antibodies (mAbs) targeting anthrax and Ebola highlight the potential of antibody-based biologics as therapeutic agents for serious infections.
耐甲氧西林金黄色葡萄球菌(MRSA)菌株介导的严重感染发病率不断上升,对公众健康构成重大风险。真正新型抗生素的发现和开发长期空白以及疫苗的缺失,加剧了这一风险。这些空白使得人们重新对使用生物制品预防和治疗严重葡萄球菌感染产生了兴趣。在本综述中,我们重点关注基于抗体的生物制剂的发现和开发工作及其作为治疗严重金黄色葡萄球菌感染临床药物的潜力。针对炭疽和埃博拉病毒的单克隆抗体(mAb)最近取得的有前景的数据,凸显了基于抗体的生物制品作为严重感染治疗药物的潜力。